MMED
MiniMed Group, Inc.
Healthcare · Health Information Services · NMS
$10.80
Close 2026-05-28
✓ ETHICAL PASS

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$3.0B
Trailing P/E
Forward P/E
16.07
Rev Growth
+15.0%
Profit Margin
-10.7%
ROE
Analyst Target
$20.50
Recommendation
STRONG BUY
About MiniMed Group, Inc.

MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue Ratio (0.00%)PASS
OverallPASS
Score Ethical: 64.7
Score Valuation: 61.0
Score Quality: 40.0
Score Combined: 43.1

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation85.0
Quality45.0
Cash Flow50.0
Moat40.0
Balance Sheet32.1
Debt Purity50.0
Liquid Purity50.0
Rev Purity100.0
Compliance100.0
Tier: BRONZE · Score: 50.2 · Rank: #1818
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$3.3B
Price/Book
0.93
Analysts
12
Total Revenue (TTM)
$3.0B
Total Debt
$61.0M
Rec. Mean
1.31
Short Ratio
6.04
Short % Float
0.2%
Employees
8,000

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 43.1 (P53 — top 46.7% of scored tickers). Unknown Moat. Ethical PASS. 12 analysts at Strong Buy.
Price: $10.80 | Target: $21.67 (+101%)
Score
43
Moat
Unknown
Conviction
Standard
Upside
+101%
The Fundamentals
Revenue Growth+15.0%
Profit Margin-10.7%
Forward P/E16.1
Market Cap$3.0B
Position Sizing Scenarios
Stop: $9.18 (-15%) | Entry: $10.80
SharesCostProfit to TargetR:R
To Consensus ($21.67, 12 analysts)
10$108.00+$108.70 (101%)6.7R
50$540.00+$543.50 (101%)6.7R
100$1,080.00+$1,087.00 (101%)6.7R
Risk Factors
  • Elevated short interest (6.04 days to cover)
The Verdict
MiniMed Group, Inc. passes all ethical screens and holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

D
Quant Score
39.5
Risk Grade
Layers
2
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
NONE
Bollinger Position
UPPER_HALF
Beta
Relative Volume
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-11.1%
3M Return
6M Return
12M Return
Momentum Rank
#3819
Momentum Signal
DOWN

Get our daily market read free. Join thousands of traders.

Free Explorer Access